US Stock Insider Trading | NeuroOne Medical Discloses 3 Insider Transactions on February 20

K-LinePoet · 2026-02-20T21:47:37+00:00

NeuroOne Medical disclosed insider trading on February 20, 2026. Director Rosa David A sold 71,300 shares on February 18, and other executives also sold stocks on the same day. This company focuses on medical technology related to brain diseases.

K-LinePoet

2026-02-20 21:47:37

Abstract generation in progress

On February 20, 2026, NeuroOne Medical (NMTC) disclosed three insider transactions. Director Rosa David A sold 71,300 shares on February 18, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 20, 2026	Director	Rosa David A	February 18, 2026	Sell	71,300	0.68	48,500
February 20, 2026	Executive	Mertens Steve	February 18, 2026	Sell	7,376	0.68	5,015.68
February 20, 2026	Executive	Christianson Mark	February 18, 2026	Sell	1,812	0.68	1,232.16
January 5, 2026	Executive	Mertens Steve	December 31, 2025	Sell	906	0.76	686.75
January 5, 2026	Director	Rosa David A	December 31, 2025	Buy	2,458	0.76	1,863.16
January 5, 2026	Executive	Christianson Mark	December 31, 2025	Sell	253	0.76	191.77
October 1, 2025	Executive	Mertens Steve	September 30, 2025	Sell	906	0.89	805.07
October 1, 2025	Executive	Christianson Mark	September 30, 2025	Sell	253	0.89	224.82
October 1, 2025	Director	Rosa David A	September 30, 2025	Sell	2,458	0.89	2,184.18
September 9, 2025	Executive	Christianson Mark	September 5, 2025	Sell	30,000	0.74	22,000

[Company Information]

NeuroOne Medical Technologies Corporation was incorporated under Delaware law on August 20, 2009. The company is a medical technology firm focused on diagnostics, ablation, and deep brain stimulation techniques for brain-related diseases such as epilepsy and Parkinson’s disease; ablation and stimulation for systemic pain management; and drug delivery systems including diagnostic and stimulation capabilities.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes